Dicerna Pharmaceuticals Inc. (DRNA) Sees Large Volume Increase
Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) shares saw strong trading volume on Friday . 226,453 shares traded hands during trading, an increase of 38% from the previous session’s volume of 163,539 shares.The stock last traded at $3.34 and had previously closed at $3.31.
A number of research analysts have recently issued reports on the stock. Chardan Capital reduced their price objective on shares of Dicerna Pharmaceuticals from $4.00 to $3.50 and set a “neutral” rating for the company in a report on Monday, August 8th. Cowen and Company reiterated a “buy” rating on shares of Dicerna Pharmaceuticals in a report on Friday, August 5th. Leerink Swann reiterated a “buy” rating on shares of Dicerna Pharmaceuticals in a report on Thursday, June 30th. Stifel Nicolaus reduced their price objective on shares of Dicerna Pharmaceuticals from $16.00 to $13.00 and set a “buy” rating for the company in a report on Thursday, June 30th. Finally, Zacks Investment Research upgraded shares of Dicerna Pharmaceuticals from a “hold” rating to a “buy” rating and set a $3.75 price target on the stock in a report on Thursday, May 12th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $11.85.
The firm has a 50-day moving average of $3.28 and a 200-day moving average of $4.42. The stock’s market cap is $71.50 million.
Dicerna Pharmaceuticals (NASDAQ:DRNA) last issued its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($0.75) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.84) by $0.09. On average, equities analysts predict that Dicerna Pharmaceuticals Inc. will post ($3.17) EPS for the current year.
Dicerna Pharmaceuticals, Inc is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.